Home » News » India » India's Glenmark to Study Potential Covid-19 Drug Combination
1-MIN READ

India's Glenmark to Study Potential Covid-19 Drug Combination

Small bottles labeled with a "Vaccine COVID-19" sticker and a medical syringe. (Reuters)

Small bottles labeled with a "Vaccine COVID-19" sticker and a medical syringe. (Reuters)

The study will look to enroll 158 hospitalized patients of moderate COVID-19 in India, the company added.

Glenmark Pharmaceuticals Ltd said on Tuesday it will begin a new clinical trial in India to test a combination of two anti-viral drugs - favipiravir and umifenovir - as a potential COVID-19 treatment.

The study will look to enroll 158 hospitalized patients of moderate COVID-19 in India, the company added.

Last month, Glenmark said it would conduct clinical trials in India of just favipiravir as a potential treatment for COVID-19.

first published:May 26, 2020, 11:11 IST